Vera Therapeutics Inc. Class A (VERA)
NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 30.25 0.00%
VERA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.18B
- EPS (TTM)
- -$5.87
- Dividend yield
- None
- 52-week range
- 23.05 – 56.05
- Day range
- 28.46 – 30.61
- Volume / Avg
- 3.29M / 2.24M
- Beta
- —
- Shares outstanding
- 72.06M
- Next earnings
- Nov 4, 2026
52-week range
VERA stock today
On Oct 7, VERA ended the session at $30.25, adding $0.83 (2.82%), versus the S&P 500's 0.22% decline. At this level, VERA sits in the middle of its 52-week range of $23.05 to $56.05: 46.0% below the high, set on Dec 24, 2025 and 31.2% above the low. VERA is down 40.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 1.8%.
Vera Therapeutics has posted a net loss over the last twelve months (EPS of -$5.87), so its P/E ratio is not meaningful. Vera Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Vera Therapeutics
Company profileVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Marshall W. Fordyce M.D.
- Headquarters
- Brisbane, CA
- Employees
- 361
- IPO year
- 2021
- Website
- veratx.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$77.50+156.20%
- Strong buy 1
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-1.72
VERA news
All VERA newsVera Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs VERA |
| VRDNViridian Therapeutics Inc. | 18.28 | +0.33% | $2.07B | vs VERA |
| SDGRSchrodinger Inc. | 27.29 | -5.57% | $2.04B | vs VERA |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs VERA |
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs VERA |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs VERA |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs VERA |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs VERA |
Indexes, lists and sector
Largest Health Care stocks
Vera Therapeutics stock FAQ
What is Vera Therapeutics's stock price today?
VERA last traded at $30.25 as of Oct 7, 4:00 PM EDT, up 2.82% on the day. Prices are delayed at least 15 minutes.
When is Vera Therapeutics's next earnings date?
Vera Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-1.72.
Who is Vera Therapeutics's CEO?
Dr. Marshall W. Fordyce M.D. is the chief executive officer of Vera Therapeutics Inc. Class A, which has about 361 employees.
What is the VERA 52-week high?
The 52-week high for VERA is $56.05 and the 52-week low is $23.05. The stock is currently 46.0% below its high.